A Phase 3, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of BID Dosing of AGN-190584 in Subjects With Presbyopia

Currently available treatments for presbyopia (old eye) include nonsurgical options (spectacles or contact lenses) and surgical options, however, each has its own risks and limitations. The purpose of this study is to evaluate how effective AGN-190584 is in treating presbyopia compared to vehicle (placebo).
AGN-190584 is an investigational drug being developed for the treatment of presbyopia. Participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to vehicle. Around 200 participants age 40-55 years with a diagnosis of presbyopia will be enrolled in the study in approximately 20 sites in the United States.
Participants will receive AGN-190584 or vehicle in each eye twice daily for 14 days.
There may be additional procedures for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a doctor's office. The effect of the treatment will be checked by medical assessments, vision/eye tests, checking for side effects and completing questionnaires.

开始日期2021-09-02

申办/合作机构

Allergan UC

JPRN-UMIN000019179

/ CompletedN/AIIT

prophylactic effect and QOL analysis of in gargling with pilocarpine and polaprezinc for radiation-induced xerostomia - prophylactic effect and QOL analysis of in gargling with pilocarpine and polaprezinc for radiation-induced xerostomia

开始日期2015-10-10

申办/合作机构

Tohoku University School of Medicine

100 项与硝酸毛果芸香碱相关的临床结果

登录后查看更多信息

100 项与硝酸毛果芸香碱相关的转化医学

登录后查看更多信息

100 项与硝酸毛果芸香碱相关的专利（医药）

登录后查看更多信息

319

项与硝酸毛果芸香碱相关的文献（医药）

2024-11-01·SENSORS AND ACTUATORS B-CHEMICAL

Precise and efficient release of pilocarpine for sweat wearables

作者: Sun, Linan ; Lou, Yafei ; Tian, Junfei ; Chen, Junhao ; Nilghaz, Azadeh ; Liu, Shan

The first step in wearable sweat sensing is to controllably acquire clean sweat within a limited space.Although some drug-induced methods such as iontophoresis can obtain clean sweat, there are still unsolved problems such as uncontrollable drug release, high operational c.d., and low integration of modules due to the separation areas of sweat secretion and sweat delivery.In this study, we propose a novel method for the controlled release of sweat-inducing drugs for wearable sweat sensors.A kind of electro-responsive screen-printed electrode has been designed, which consists of a hybrid layer composed of 3,4-Ethylenedioxythiophene, pilocarpine nitrate, and nadroparin calcium and an electrowetting layer of polymerized 3-methylthiophene.This efficient electrode can achieve a controllable release d. of up to 9.395μg·cm^-2 for sweat-inducing pilocarpine within 10 min and operates at microampere levels.Furthermore, we utilized the voltage drift of Ag/AgCl electrode at varying chloride ion concentrations to achieve an estimation of chloride level in sweat for possible cystic fibrosis screening.The elec. controlled drug release, electrowetting, and electrochem. detection were integrated into a single three-electrode system first.This study is expected to promote the development of miniaturized, integrated, and non-invasive wearable biosensors for sweat monitoring.

2023-03-01·American journal of physiology. Regulatory, integrative and comparative physiology

Effect of reflex and mechanical decreases in skin perfusion on thermal- and agonist-induced eccrine sweating in humans

Article

作者: Narra, Seetharam C. ; Alibegovic, Kenan ; Dazé, Robert P. ; Metzler-Wilson, Kristen ; Miller, Olivia G. ; Wilson, Thad E. ; Daggett, James W. ; Fang, Milie M.

In humans, skin blood flux (SkBF) and eccrine sweating are tightly coupled, suggesting common neural control and regulation. This study was designed to separate these two sympathetic nervous system end-organ responses via nonadrenergic SkBF-decreasing mechanical perturbations during heightened sudomotor drive. We induced sweating physiologically via whole body heat stress using a high-density tube-lined suit ( protocol 1; 2 women, 4 men), and pharmacologically via forearm intradermal microdialysis of two steady-state doses of a cholinergic agonist, pilocarpine ( protocol 2; 4 women, 3 men). During sweating induction, we decreased SkBF via three mechanical perturbations: arm and leg dependency to engage the cutaneous venoarteriolar response (CVAR), limb venous occlusion to engage the CVAR and decrease perfusion pressure, and limb arterial occlusion to cause ischemia. In protocol 1, heat stress increased arm cutaneous vascular conductance and forearm sweat rate (capacitance hygrometry). During heat stress, despite decreases in SkBF during each of the acute (3 min) mechanical perturbations, eccrine sweat rate was unaffected. During heat stress with extended (10 min) ischemia, sweat rate decreased. In protocol 2, both pilocarpine doses (ED50 and EMAX) increased SkBF and sweat rate. Each mechanical perturbation resulted in decreased SkBF but minimal changes in eccrine sweat rate. Taken together, these data indicate that a wide range of acute decreases in SkBF do not appear to proportionally decrease either physiologically- or pharmacologically induced eccrine sweating in peripheral skin. This preservation of evaporative cooling despite acutely decreased SkBF could have consequential impacts for heat storage and balance during changes in body posture, limb position, or blood flow restrictive conditions.

2021-09-01·Bioengineering & translational medicine1区 · 工程技术

Administration of pilocarpine by microneedle patch as a novel method for cystic fibrosis sweat testing

1区 · 工程技术

ArticleOA

作者: Guglani, Lokesh ; Li, Song ; Ryan, Clare A. ; Norton, Natalie ; Hart, Kelsey ; Prausnitz, Mark R.

Abstract:

The sweat test is the gold standard for the diagnosis of cystic fibrosis (CF). The test utilizes iontophoresis to administer pilocarpine to the skin to induce sweating for measurement of chloride concentration in sweat. However, the sweat test procedure needs to be conducted in an accredited lab with dedicated instrumentation, and it can lead to inadequate sweat samples being collected in newborn babies and young children due to variable sweat production with pilocarpine iontophoresis. We tested the feasibility of using microneedle (MN) patches as an alternative to iontophoresis to administer pilocarpine to induce sweating. Pilocarpine‐loaded MN patches were developed. Both MN patches and iontophoresis were applied on horses to induce sweating. The sweat was collected to compare the sweat volume and chloride concentration. The patches contained an array of 100 MNs measuring 600 μm long that were made of water‐soluble materials encapsulating pilocarpine nitrate. When manually pressed to the skin, the MN patches delivered >0.5 mg/cm2 pilocarpine, which was double that administered by iontophoresis. When administered to horses, MN patches generated the same volume of sweat when normalized to drug dose and more sweat when normalized to skin area compared to iontophoresis using a commercial device. Moreover, both MN patches and iontophoresis generated sweat with comparable chloride concentration. These results suggest that administration of pilocarpine by MN patches may provide a simpler and more‐accessible alternative to iontophoresis for performing a sweat test for the diagnosis of CF.

项与硝酸毛果芸香碱相关的新闻（医药）

2023-01-04

·BioSpace

Orasis Pharmaceuticals Submits New Drug Application for Investigational Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopia

PONTE VEDRA, Fla., Jan. 3, 2023 /PRNewswire/ -- Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing a unique eye drop to improve near vision for people with presbyopia, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational CSF-1 (low dose pilocarpine hydrochloride 0.4%). "This NDA submission is a significant milestone for Orasis as we advance CSF-1 towards commercialization and achieving our goal of reshaping vision possibilities for patients," said Elad Kedar, Chief Executive Officer of Orasis Pharmaceuticals. "With more than 120 million people in the U.S. affected, we look forward to working with the FDA during its review process to ultimately provide an alternative treatment option for patients seeking flexibility in managing their presbyopia." The NDA is based on data from the Phase 3 NEAR-1 and NEAR-2 clinical trials, involving more than 600 patients, which evaluated the efficacy and safety of CSF-1. Both trials met their primary and key secondary endpoints on Day 8, achieving statistically significant 3-line or more gain in distance-corrected near visual acuity (DCNVA), and no loss of 1-line or more in distance visual acuity. The most common treatment-related adverse events of headache and instillation site pain occurred in only 6.8% and 5.8% of participants, respectively. Of all CSF-1 participants, only 2.6% reported moderate treatment-related adverse events. All other adverse events were mild. The Phase 3 NEAR-1 and NEAR-2 top-line results were previously announced earlier this year, and additional details of these studies will be presented at future medical meetings. About CSF-1 CSF-1 is a novel corrective eye drop candidate being investigated for the treatment of presbyopia. CSF-1 is a proprietary, preservative-free formulation of low-dose pilocarpine and multi-faceted vehicle designed to achieve an optimal balance between efficacy, safety and comfort. CSF-1 improves near visual acuity by pupil modulation, resulting in a "pinhole effect" and an increase in the depth of field, thus increasing the ability to focus on near objects. About Presbyopia Presbyopia is the loss of ability to focus on near objects as a result of the natural aging process. It occurs mostly after the age of 40 when the crystalline lens of the eye gradually stiffens and loses flexibility. There are almost two billion people globally and more than 120 million people in the U.S. living with presbyopia. People with presbyopia experience blurred vision when performing daily tasks that require near visual acuity, such as reading a book, a restaurant menu, or messages on a smartphone. Presbyopia cannot be prevented or reversed, and it continues to progress gradually. Many existing treatment options can be either cumbersome or invasive, presenting a significant unmet need for quality-of-life improvement for people with presbyopia. About Orasis Pharmaceuticals Orasis Pharmaceuticals is developing CSF-1, a corrective eye drop for the treatment of presbyopia. Orasis is led by a collaborative team of industry executives and eye care specialists with a broad range of experiences in research, development, and commercialization of pharmaceutical drugs, as well as finance and business development. Orasis is funded by a diverse group of sophisticated and experienced life science and healthcare investors including the ophthalmology focused venture capital fund Visionary Ventures, Sequoia Capital, SBI (Japan) Innovation Fund, Bluestem Capital, LifeSci Venture Partners, Maverick Ventures Israel, and other private investors. Orasis has offices in the U.S. and Israel. For more information, visit and connect with us on LinkedIn.

临床结果申请上市临床3期

2022-08-17

·CPhI制药在线

金笔奖 | 从2022H1业绩，看自免巨头艾伯维的业绩增长逻辑

关注并星标CPHI制药在线 7月29日，艾伯维公布2022H1业绩，上半年总收入281.21亿美元，同比增长4.3%。2022 Q2收入145.83亿美元，同比增长4.5%。截图来源：2022H1 艾伯维财报艾伯维当前的业务主要聚焦在自身免疫疾病、血液肿瘤、美容、神经疾病、眼科疾病、妇女保健几个方向。其中自身免疫疾病的份额已超半壁江山，上半年收入133.48亿美元，同比增长12.5%，占总收入的47.5%。血液肿瘤业务收入32.96亿美元，同比降低5.5%；神经科学领域业务收入31.46亿美元，同比增加16.2%；美容业务收入27.45亿美元，同比增加6.6%；眼科产品收入14.88亿美元，同比减少14.3%。截图来源：2022H1 艾伯维财报事实上，2021年，艾伯维就以561.97亿美元的业绩跻身全球药企500亿美元俱乐部，今年颇有赶超之势。作为成立不到十年的新贵公司（2013年成立），其业绩增长速度令人咋舌。那么，艾伯维的业绩增长逻辑究竟是什么？它的成功给国内药企带来什么启示？为拳头产品修美乐（Humira）建立专利丛林提到艾伯维，就不得不提老药王修美乐。这是全球第一个获批上市的抗TNF-α全人源抗体药物。自2002年底在美国批准上市以来，收入近2000亿美元，是名副其实的药王。尽管修美乐分子式专利已于2016年到期，但是通过一系列操作，艾伯维使得修美乐在美国的合法垄断权在2016年后延长了6 年。从那时起，修美乐在美国的销售额已达到近750亿美元。艾伯维在美国提交了247项与修美乐相关的专利申请，其中100多项被授予通过。其专利设置详细至极，例如包括在所有适应证中的使用方法、配制和制备药物的方法，药物递送装置等。同时，艾伯维还声称他们的药物已经产生变化，这样可以通过产生新的法律保护以阻止生物类似药竞争对手的上市。艾伯维的这一策略非常有效，从2019年到2021年，修美乐仅在美国的销售额就达到近500亿美元。2021年全年销售额为206.96亿美元。2022年上半年销售额达到100.99亿美元，同比增长1.7%，今年仍有望继续突破200亿美元大关。免疫双子星Skyrizi和Rinvoq接力修美乐，为专利悬崖上双保险尽管艾伯维为修美乐建立了坚实的专利丛林，但仍不可避免专利悬崖的到来。修美乐将于2023年1月在美国遭遇第一批生物类似药竞争。届时，不可避免的将对修美乐的业绩造成冲击。不过深耕自免领域多年的艾伯维已经做好了准备。自免管线中另两款产品IL-23单抗Skyrizi (瑞莎珠单抗)和口服JAK1抑制剂Rinvoq (乌帕替尼)已经做好准备接棒修美乐。 Skyrizi于2021年11月被EMA批准单药或联合甲氨蝶呤（MTX）用于治疗对一种或多种疾病修饰抗风湿药物（DMARD）应答不足或不耐受的成人活动性银屑病关节炎（PsA）。在美国，FDA于2021年4月批准Skyrizi用于治疗中度至重度斑块型银屑病成人患者，同时，今年上半年，Skyrizi获得FDA两项监管批准，分别用于治疗成人活动性银屑病关节炎（PsA）和中重度克罗恩病（CD）的治疗。2022上半年，Skyriz收入21.92亿美元，同比增长75.7%。 Rinvoq于2021年1月被EMA批准用于治疗对一种或多种疾病修饰抗风湿药物（DMARD）应答不足或不耐受的活动性银屑病关节炎（PsA）成人患者，以及用于治疗对常规疗法应答不足的活动性强直性脊柱炎（AS）成人患者。2021年12月，Rinvoq被FDA批准用于治疗对一种或多种肿瘤坏死因子（TNF）阻断剂应答不足或不耐受的成人PsA。 2021年，虽然因JAK抑制剂的安全性风险，其在美国多项新适应证上市申请一度遭到延期。不过在FDA要求JAK产品添加黑框警告后，去年末至今年Rinvoq多项适应证顺利在美国陆续批准，包括用于治疗PsA、中重度特应性皮炎、中重度溃疡性结肠炎(UC)、强直性脊柱炎(AS)。Rinvoq上半年的销售收入也显著增长，达到10.57亿美元，同比增长55.1%。艾伯维对Skyrizi和Rinvoq两款产品抱有很大期待，预计它们2025年的销售额有望达到150亿美元。第二大板块——肿瘤领域艾伯维已将肿瘤领域列为自免之外的第二大板块。其BTK抑制剂Imbruvica（依布替尼）和Bcl-2抑制剂Venclexta（维奈克拉）是艾伯维血液肿瘤领域的两款重要产品。艾伯维在2021年赢得了Imbruvica专利诉讼与仿制药厂商达成和解，保证了在 2032 年 3 月 30 日之前不会有 Imbruvica 仿制药产品进入美国。然而，由于市场竞争加剧等原因，Imbruvica在2022上半年收入出现明显下滑，为23.18亿美元，同比降低12.5%。不过Venclexta作为目前全球唯一上市的Bcl-2抑制剂，尚无竞品出现，2021年其总销售收入18.2亿美元，同比增长36.1%。今年依然保持较好的增长势头，上半年收入达到9.78亿美元，同比增长16.5%。为艾伯维打下另一块阵地。除了现有的血液肿瘤产品外，艾伯维还在扩大肿瘤领域管线储备，此前已与Genmab达成39亿美元合作，引进双特异性抗体药物epcoritamab以及ABBV-383，目前正在临床试验中。多点开花，神经疾病、眼科领域全布局在神经疾病领域，艾伯维曾斥资630亿美元收购Allergan，并获得其偏头痛产品Ubrelvy（ubrogepant），这是FDA批准的首个用于偏头痛急性治疗的口服CGRP受体拮抗剂，2022年上半年收入达到3.23亿美元。公司另一款偏头痛新药Qulipta（atogepant）也是一种CGRP受体拮抗剂，于去年9月获FDA批准上市，作为间歇性偏头痛的预防性治疗药物，今年上半年取得了4400万美元的收入。由于Qulipta能同时用于发作性偏头痛和慢性偏头痛的治疗，因此，未来将覆盖更广泛的人群，同时也将成为辉瑞Nurtec的强劲对手。除此之外，艾伯维于今年5月向FDA提交了ABBV-951（foslevodopa/foscarbidopa）皮下注射剂的上市申请，用于治疗晚期帕金森病患者的运动症状波动，帮助他们更加稳定地控制运动症状。在眼科领域，Restasis是唯一一款销售额超10亿美元的重磅药物。Restasis于2002年获批上市，用于干眼症的治疗，已建立了足够的市场认知度。不过随着Restasis的专利即将到期，国内和国外的仿制药已经蠢蠢欲动。今年上半年，Restasis的销售额为4.14亿美元。 Vuity是艾伯维眼科管线的另一重要产品，该药是毛果芸香碱（M-胆碱受体激动剂）的一种新的优化配方，专门设计用于治疗老花眼，通过收缩瞳孔来增强聚焦深度，改善近视力和中视力，同时保持瞳孔对不同光照条件的反应。2021年10月，该药获FDA批准用于治疗老花眼，成为首个专门用于治疗老花眼的滴眼液。此外，2021年9月，艾伯维与Regenxbio达成合作，共同开发、商业化RGX-314，而该药是一种潜在的一次性基因疗法，用于治疗湿性年龄相关性黄斑变性 (wAMD)、糖尿病性视网膜病变 (DR) 和其他慢性视网膜疾病。毫无疑问，艾伯维现已成为免疫学、肿瘤学、神经科学、眼科学、医美等多个领域的市场佼佼者。从其管线布局，我们可以看出：要想成为药企巨头，既要有自己过硬的拳头产品，又要多点开花，在多个黄金赛道强势出击。艾伯维目前仍在采取多种手段拓展其管线，产品涉及小分子、抗体和细胞疗法等，一个多元化的制药巨头正在奋力成长。同时也告诉我们，想要成为世界巨头药企，对外扩张/合作必不可少。参考来源： 1.2022H1 艾伯维财报； 2.https://www.biospace.com/article/abbvie-acquires-belgium-s-syndesi-therapeutics-and-its-neurodegenerative-disease-assets-/； 3.https://medcitynews.com/2022/03/abbvie-makes-neuro-drug-connection-with-130m-syndesi-therapeutics-acquisition/； 4.V u i t y (p i l o c a r p i n e HCI ophthalmic solution) 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry Near Vision (Presbyopia), is Now Available. 作者简介：@叶枫红，生化背景，曾从事抗肿瘤药物的研发工作。很高兴能够通过CPhi制药在线平台，以多维角度来分享医药产业的动态，探讨热点话题，发表自己的观点。希望读者朋友能喜欢我的作品。智药研习社8月直播讲座报名来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com▼更多制药资讯，请关注CPhI制药在线▼点击阅读原文，进入智药研习社~

财报抗体合作免疫疗法生物类似药

2022-07-07

·PRNewswire

Arctic Vision Announces First Patient Enrolled in Phase III Clinical Trial of ARVN003 for Presbyopia

SHANGHAI, July 4, 2022 /PRNewswire/ -- Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, today announced that the first patient has been enrolled in a Phase III clinical study evaluating ARVN003, a proprietary pilocarpine formulation leveraging its micro dosing platform Optejet®, as a treatment to temporarily improve vision in adults with presbyopia in China. The Phase III study is double-masked, placebo-controlled, randomized, and multicenter trial evaluating the efficacy and safety of ARVN003 in achieving temporary improvement of vision in adults with presbyopia. It is the first clinical trial approved in China for presbyopia drugs and Arctic Vision's study marks the first patient enrollment in a Phase III clinical trial for presbyopia drugs in China. Presbyopia is a physiological condition that makes it difficult to read and work in near distance. It is caused by the hardening of the lens and weakening of the ciliary muscle and often occurs with aging. Pre-presbyopia typically affects people between the ages of 35 and 45; early presbyopia affects people between the ages of 45 and 52; and late presbyopia, also known as absolute presbyopia, affects people over the age of 52. Today, nearly a quarter of the world's population is affected by presbyopia. With China's rapidly ageing population, the nation is seeing a year-on-year increase in the number of people suffering from presbyopia. Latest data revealed more than 390 million people in China are diagnosed with presbyopia in 2021. Current treatment options for presbyopia include presbyopic reading glasses, contact lenses and surgery. However, due to limited treatment options and inadequate scientific understanding of the disease, many presbyopia patients in China do not receive intervention or vision correction in time. Untreated and escalated, presbyopia adversely impacts vision, quality of work and life, and the psychological well-being of middle-aged and elderly people. It might also increase financial burden on families and society. Professor Jia Qu, the Principal Investigator and renowned leader in China's ophthalmology sector – President of Eye Hospital of Wenzhou Medical University said, "With China's rapidly aging population and a growing number of younger presbyopia patients, there is exponential demand for effective, safe, and convenient presbyopia treatments. We are excited to lead China's first clinical study of presbyopia medication and look forward to the approval of ARVN003 in the near future." Dr. Qing Liu, Co-Founder and Chief Medical Officer at Arctic Vision added, "ARVN003's significant clinical progress is encouraging. This clinical achievement follows the successful dosing of the first DME patient in Asia with 锋脉® (Feng Mai) or Arcatus™ (ARVN001), and is testimony of the strength of Arctic Vision's proprietary microdose array print (MAP™) technology in the public eye health sector. We strive to make ARVN003 the first approved presbyopia drug in China, and benefit more presbyopia patients with innovative and diverse treatment options that will help them see and live better." Arctic Vision obtained an exclusive license in August 2020 for the development and commercialization of ARVN003 (MicroLine) in Greater China and South Korea from Eyenovia, a U.S.-based clinical-stage biopharma company. In May 2021, Eyenovia announced positive results from the first Phase 3 MicroLine study, VISION-1, in the U.S. In that trial, the primary endpoint was achieved with MicroLine 2% statistically superior to placebo, determined by improvement in high contrast binocular distance corrected near visual acuity measured in low light conditions two hours after treatment. About ARVN003 ARVN003 is a proprietary pilocarpine formulation leveraging microdosing platform Optejet® for the pharmacologic treatment for presbyopia. Pilocarpine ophthalmic solution is known to constrict the pupil and improve near-distance vision by creating an extended depth of focus through its small aperture effect. The administration of pilocarpine uses high-precision microdosing platform Optejet® to provide improvement in near vision while enhancing tolerability and usability. About Optejet® Optejet uses high-precision piezo-print technology to deliver approximately 8μL of drug, consistent with the capacity of the tear film of the eye. The volume of ophthalmic solution administered with the Optejet is 80% less than that delivered using conventional eye drops, thus reducing overdosing and exposure to drug and preservatives. Eyenovia's patented microfluidic ejection technology, MAP™ is designed for fast ocular surface delivery, where medication is dispensed as an array of microdroplets to the ocular surface in approximately 80 milliseconds, faster than the ocular blink reflex. Ease of use and successful delivery of medication by Optejet has been demonstrated in more than 85% of the attempts after basic training in a variety of clinical settings compared to 40 – 50% with conventional eyedroppers[i]. Additionally, its smart electronics and mobile e-health technology are designed to track and enhance patient compliance. [i] Pasquale LR, Lin S, Weinreb RN, et al. Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose. Clin Ophthalmol. 2018 Nov 28; 12:2451-2457. About Arctic Vision Arctic Vision is a China-based ophthalmic biotech focusing on breakthrough therapies, with a leading portfolio covering pre-clinical stage to commercial stage products. Our vision is to provide innovative therapies in China, Asia and globally to address unmet clinical needs and benefit ophthalmic patients at large. Arctic Vision is supported by top-tier life sciences investors and led by an elite team of ophthalmic industry veterans with substantial regional and global experiences in R&D and commercialization of ophthalmic products. For more information, please visit https://www.arcticvision.com

引进/卖出

100 项与硝酸毛果芸香碱相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05478	-	S01EB01 N07AX01	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
青光眼	中国	津药和平（天津）制药有限公司	1981-01-01
虹膜炎	中国	津药和平（天津）制药有限公司	1981-01-01
瞳孔散大	中国	津药和平（天津）制药有限公司	1981-01-01
斜视	中国	津药和平（天津）制药有限公司	1981-01-01
口干症	中国	津药和平（天津）制药有限公司	1981-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
老花眼	临床前	中国	北京诺思兰德生物技术股份有限公司	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04983589 (Virgo, CTgov)	临床3期	老花眼	230	Vehicle (Vehicle)	鬱鑰襯壓襯齋選築醖餘 = 鑰淵構鹽選鑰鬱膚糧製壓願鑰窪襯觸製觸願醖 (餘憲選遞廠醖艱願製觸, 壓夢製遞鹹鬱選齋糧鬱 ~ 衊築範餘遞顧觸鹹簾遞) 更多	-	2023-03-21
NCT04983589 (Virgo, CTgov)	临床3期	老花眼	230	Pilocarpine HCl (AGN-190584)	鬱鑰襯壓襯齋選築醖餘 = 夢範憲鹹醖齋觸繭構鹽壓願鑰窪襯觸製觸願醖 (餘憲選遞廠醖艱願製觸, 築蓋鹹憲餘鹹淵獵遞壓 ~ 鑰鹹壓觸範獵鹹鹽繭鹹) 更多	-	2023-03-21
NCT02310789 (CTgov)	N/A	囊性纤维化	8	Macroduct sweat stimulator+Ivacaftor+Pilocarpine Nitrate 5%	鏇蓋憲構壓齋膚網憲網(遞餘壓簾簾構鹽築鑰築) = 艱觸廠範醖簾夢膚鏇膚淵觸淵獵網廠範壓鏇餘 (齋簾膚鏇糧鹹糧選鑰簾, 2.25) 更多	-	2018-04-20